, kidney artery stenosis) Compelling indications include: CKD with albuminuria (refer to VA/DoD CKD ); HFrEF; recent MI Long-Acting Calcium Channel Blockers (CCB) DHP CCBs Amlodipineb Felodipine Nifedipine sustained releaseb Non-DHP CCBs Verapamil sustained releaseb Diltiazem sustained releaseb 2.5-10 mg daily 2.5-10 mg daily 30-120 mg daily 120-480 mg divided daily- bid 120-540 mg daily Monitor AEs (DHP CCBs may cause ankle edema, dizziness, flushing, headache, constipation) Use with caution in patients with hepatic (CCBs) or kidney (non-DHP CCBs) dysfunction Non-DHP CCBs may be considered for rate control in supraventricular tachycardia or atrial fibrillation/flutter Verapamil may cause constipation; verapamil is contraindicated 2nd or 3rd degree AV block, severe LV dysfunction Diltiazem may decrease sinus rate; diltiazem is contraindicated in 2nd degree AV block; use with caution in LV dysfunction Verapamil or diltiazem should not usually be used with a beta-blocker due to risk of severe bradycardia or heart block 2 See the VA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease. Available at: https://www.healthquality.va.gov/guidelines/CD/CKD/ Drug Usual Dose Range Commentsa Aldosterone/ Mineralocorticoid Receptor Antagonists Eplerenoned Spironolactoneb 50-100 mg/day (daily or divided bid) Avoid use if hyperkalemia or severe kidney dysfunction Monitor K+ and kidney function; consider risk vs. benefit if combined with ACEI, ARB, K+ sparing diuretic, or K+ supplement Higher risk of gynecomastia with spironolactone (9%) than eplerenone Compelling indications include: HFrEF Effective in resistant hypertension Other Potassium- Sparing Diuretics Amiloride 5-10 mg/daily Avoid use if hyperkalemia or severe kidney dysfunction Helpful in reducing hypokalemia caused by thiazide diuretics Effective in resistant hypertension Alpha-Adrenergic Blockers Doxazosin Prazosin Terazosinb 2-20 mg/day (divided bid or tid) 1-20 mg daily Initiate at low doses (1 mg) Administer 1st dose at bedtime to avoid syncope Avoid use as monotherapy May be considered for use in patients with symptomatic BPH Beta-Adrenergic Blockers Noncardioselective Propranolol Cardioselective Atenololb Metoprolol tartrateb Metoprolol succinate (XL)b Combined alpha- beta adrenergic blockers Carvedilol Labetalold Immediate release: 80-160 mg/day (divided bid) Sustained release: 80-160 mg daily 25-100 mg daily (adjust dose in CKD) Immediate release: 50-300 mg/day (daily or divided bid) Sustained release: Immediate releaseb : 12.5-50 mg/day (divided bid) Sustained released : 200-800 mg/day (divided bid) Discontinue with slow taper over one week Avoid combination with non-DHP CCB due to increased risk of bradycardia or heart attack As doses increase, cardioselectivity decreases Beta-blockers should be used cautiously in asthma Compelling indications include: HFrEF (evidence available for reduction in morbidity and mortality with bisoprolol, carvedilol, metoprolol succinate in HFrEF); recent MI; angina; rate control in atrial fibrillation/flutter; data available for select beta-blockers for migraine prevention Drug Usual Dose Range Commentsa Direct Acting Vasodilators Minoxidil Hydralazineb 2.5-100 mg/day (daily or divided bid) 50-200 mg/day (divided bid) Monitor for hypertrichosis, volume retention, and pericardial effusions with minoxidil Monitor for headache and SLE (dose- related) with hydralazine Direct acting vasodilators often require concomitant use of diuretic and beta- blocker to reduce edema and reflex tachycardia Centrally Acting Antiadrenergic Drugs Clonidine Tabletb Clonidine Patch Methyldopa 0.1-0.8 mg/day (divided bid) mg patch weekly (divided bid) Monitor for bradycardia, somnolence, and dry mouth.


Taper dose to discontinue Clonidine patches may be useful in select patients May rarely cause bone marrow depression, positive Coombs test, hemolytic anemia and liver disorders (hepatitis, jaundice) a For complete drug information, review the manufacturer s prescribing information b DoD Basic Core Formulary item c HCTZ 12.5 mg may be considered as an initial dose with titration recommended to 25-50 mg daily; refer to Recommendation 25 and associated discussion for further information d Item not on VA National Formulary e Restricted to treatment of patients with systolic heart failure in VA Abbreviations: ACEI: angiotensin-converting enzyme inhibitor; AE: adverse effect; ARB: angiotensin II receptor blocker; AV: atrioventricular; bid: twice daily; BPH: benign prostatic hyperplasia; CCB: calcium channel blockers; CKD: chronic kidney disease; CV: cardiovascular; DHP: dihydropyridine; eGFR: estimated glomerular filtration rate; HCTZ: hydrochlorothiazide; HFrEF: heart failure with reduced ejection fraction; K+: potassium; LV: left ventricular; mL: milliliter; SLE: systemic lupus erythematosus; Appendix G: Guidance for Conducting Office Blood Pressure Measurement The following information has been adapted from the 2019 AHA Measurement of Blood Pressure in Properly prepare the patient Have the patient relax, sitting in a chair with feet flat on floor and back supported; the patient should be seated for 3-5 minutes without talking or moving around before recording the first blood pressure reading The patient should avoid caffeine, exercise, and smoking for at least 30 minutes before measurement Ensure that the patient has emptied his/her bladder Neither the patient nor the observer should talk during the rest period or during the measurement Remove clothing covering the location of cuff placement Measurements made while the patient is sitting on an examining table do not fulfill these criteria Use proper technique for blood pressure measurements Use an upper-arm cuff blood pressure measurement device that has been validated and ensure that the device is calibrated periodically Support the patient s arm (e.g.


, resting on a desk); the patient should not be holding his/her arm because isometric exercise will affect the blood pressure levels Position the middle of the cuff on the patient s upper arm at the level of the right atrium (midpoint of the sternum) Use the correct cuff size such that the bladder encircles 75%-100% of the arm Table G-1. Proper Blood Pressure Cuff Sizes Cuff Size Arm Circumference (cm) Bladder Dimension (width x length, cm) Abbreviation: cm: centimeter Take the proper measurements needed for diagnosis and treatment of elevated blood pressure/hypertension At the first visit, record blood pressure in both arms; use the arm that gives the higher reading for subsequent readings (if consistently 10-15 mm Hg higher) Separate repeated measurements by at least 30 seconds Properly document accurate blood pressure readings Record SBP and DBP Note the time that the most recent blood pressure medication was taken before measurements Use average the readings Use an average of 2 readings for the visit blood pressure For initial documentation of the patient s blood pressure, use an average of the visit blood pressures obtained on 2 occasions to estimate the individual s blood pressure Provide blood pressure readings to patient Provide patients their SBP/DBP readings both verbally and in writing; someone should help the patient interpret the results What is above should be common to each appropriate standardized office blood pressure measurement technique.


Proper Blood Pressure Cuff Sizes Cuff Size Arm Circumference (cm) Bladder Dimension (width x length, cm) Abbreviation: cm: centimeter Take the proper measurements needed for diagnosis and treatment of elevated blood pressure/hypertension At the first visit, record blood pressure in both arms; use the arm that gives the higher reading for subsequent readings (if consistently 10-15 mm Hg higher) Separate repeated measurements by at least 30 seconds Properly document accurate blood pressure readings Record SBP and DBP Note the time that the most recent blood pressure medication was taken before measurements Use average the readings Use an average of 2 readings for the visit blood pressure For initial documentation of the patient s blood pressure, use an average of the visit blood pressures obtained on 2 occasions to estimate the individual s blood pressure Provide blood pressure readings to patient Provide patients their SBP/DBP readings both verbally and in writing; someone should help the patient interpret the results What is above should be common to each appropriate standardized office blood pressure measurement technique. The following are additional guidance specific for each technique: For fully automated office oscillometric manometer readings: Preprogram the manometer to wait five minutes before inflation begins and to take and average 2-3 readings at least 30 seconds apart; the most common intervals are 30 seconds, one minute, and two minutes Position the patient and place the proper sized cuff on the upper arm before initiating the wait time and blood pressure readings Turn the manometer on and set controls to take inflate to proper level (above sensed SBP) automatically and measure and average multiple readings; press the button to initiate wait period and automated readings (fully automated) Patient should remain quiet and not use electronic devices (e.g.


The following are additional guidance specific for each technique: For fully automated office oscillometric manometer readings: Preprogram the manometer to wait five minutes before inflation begins and to take and average 2-3 readings at least 30 seconds apart; the most common intervals are 30 seconds, one minute, and two minutes Position the patient and place the proper sized cuff on the upper arm before initiating the wait time and blood pressure readings Turn the manometer on and set controls to take inflate to proper level (above sensed SBP) automatically and measure and average multiple readings; press the button to initiate wait period and automated readings (fully automated) Patient should remain quiet and not use electronic devices (e.g., phones) during the rest period and readings; person measuring the blood pressure may remain in the room (attended) or leave the patient alone in the room (unattended), but no one should interact or speak with the patient during the rest period and readings After the rest and measurements are completed, record the average blood pressure reading displayed; manometer should display the average of the 2-3 readings (as preset) For standard technique with automated oscillometric device: Use an upper-arm cuff oscillometric device that has been validated Position the patient and place the proper sized cuff on the upper arm before initiating the wait time and blood pressure readings Turn the manometer on and set controls to take/inflate to proper level (above sensed SBP) automatically Patient should remain quiet and not use electronic devices (e.g.


, phones) during the rest period and readings; person measuring the blood pressure may remain in the room (attended) or leave the patient alone in the room (unattended), but no one should interact or speak with the patient during the rest period and readings After the rest and measurements are completed, record the average blood pressure reading displayed; manometer should display the average of the 2-3 readings (as preset) For standard technique with automated oscillometric device: Use an upper-arm cuff oscillometric device that has been validated Position the patient and place the proper sized cuff on the upper arm before initiating the wait time and blood pressure readings Turn the manometer on and set controls to take/inflate to proper level (above sensed SBP) automatically Patient should remain quiet and not use electronic devices (e.g., phones), and no one should speak with the patient during the rest period and readings After the five-minute rest period, push the button to initiate the first inflation/reading; record SBP and DBP reading Take the next reading(s) with at least a 30 second interval between readings and record SBP and DBP readings displayed for each reading; record the average or median SBP and average or median DBP as the patient s blood pressure For standard auscultatory technique with manual manometer: Use an upper-arm cuff manual device that has been validated and recently calibrated; this includes a mercury manometer, an aneroid manometer, or an electronic manual non-oscillometric manometer for auscultatory determinations Position the patient and place the proper sized cuff on the upper arm before initiating the wait time and blood pressure readings Patient should remain quiet and not use electronic devices (e.g.


, phones), and no one should speak with the patient during the rest period and readings After the five-minute rest period, push the button to initiate the first inflation/reading; record SBP and DBP reading Take the next reading(s) with at least a 30 second interval between readings and record SBP and DBP readings displayed for each reading; record the average or median SBP and average or median DBP as the patient s blood pressure For standard auscultatory technique with manual manometer: Use an upper-arm cuff manual device that has been validated and recently calibrated; this includes a mercury manometer, an aneroid manometer, or an electronic manual non-oscillometric manometer for auscultatory determinations Position the patient and place the proper sized cuff on the upper arm before initiating the wait time and blood pressure readings Patient should remain quiet and not use electronic devices (e.g., phones), and no one should speak with the patient during the rest period and readings Use a palpated estimate of radial pulse obliteration pressure (disappearance or resumption of pulse when cuff is inflated/deflated) to estimate SBP; inflate the cuff 20-30 mm Hg above this level to perform the auscultatory determination of the blood pressure level Use either the stethoscope diaphragm or bell for auscultatory readings After the five-minute rest period, inflate the cuff and use auscultation to determine SBP and DBP; determine SBP and DBP as the onset of the first of at least two consecutive Korotkoff sounds (beats) and the last audible Korotkoff sound, respectively Record the SBP and DBP reading Take the next reading(s) with at least a 30 second interval between readings and record SBP and DBP readings for each reading; record the average or median SBP and average or median DBP as the patient s blood pressure Appendix H: Guidance for Conducting Home Blood Pressure Measurement The following information has been adapted from the 2019 AHA Measurement of Blood Pressure in Patient training provided by healthcare staff or providers: Provide information about hypertension diagnosis and treatment Provide information on the proper selection of a device Provide instruction on how patients can measure their own blood pressure (if possible, demonstrate the procedure or instruct how to access training video) Provide instruction that the HBPM device and blood pressure readings (log or electronic recording) should be brought to healthcare visits Provide education that individual blood pressure readings may vary greatly (high and low) across the monitoring period Preferred devices and cuffs: Use an upper-arm cuff oscillometric device that has been validated Use a device that is able to automatically store all readings, if possible Use a device that can print results or can send blood pressure values electronically to the healthcare provider, if possible Use a cuff that is appropriately sized for the patient s arm circumference Table H-1.


Proper Blood Pressure Cuff Sizes Cuff Size Arm Circumference (cm) Bladder Dimension (width x length, cm) Abbreviation: cm: centimeter Best practices for the patient: Preparation Have an empty bladder Rest quietly in seated position with back supported (e.g., leaning back in chair) for at least five minutes Do not talk or text Position Sit with back supported Keep both feet flat on the floor Legs should not be crossed Blood pressure cuff should be placed on bare arm (not over clothes) Blood pressure cuff should be placed directly above the antecubital fossa (bend of the arm) Center of the bladder of the cuff (commonly marked on the cuff by the manufacturer) should be placed over the arterial pulsation of the patient s bare upper arm Cuff should be pulled taut, with comparable tightness at the top and bottom edges of the cuff, around the bare upper arm The arm with the cuff should be supported on a flat surface such as a table Number of readings Take two readings at least one minute apart in the morning before taking any antihypertensive medications and two readings at least one min apart in the evening before going to bed; some recommend only recording the second measurement Duration of monitoring Preferred monitoring period is 7 days (i.e., 28 readings or more scheduled readings); a minimum period of three days (i.e.


, 28 readings or more scheduled readings); a minimum period of three days (i.e., 12 readings) may be sufficient, ideally in the period immediately before the next appointment with provider Monitoring conducted over consecutive days is ideal; however, readings taken on nonconsecutive days may also provide valid data Analyzing readings For each monitoring period, the average of all readings should be obtained Some guidelines and scientific statements recommend excluding the first day of readings; if the first day of readings is excluded, the minimum and preferred periods of HBPM should be four and eight days, respectively For a video developed for patients by the VA and DoD with instructions on measuring blood pressure at home, please visit https://www.healthquality.va.gov/guidelines/CD/htn/ and click on the Home Blood Pressure Monitoring video.


, 12 readings) may be sufficient, ideally in the period immediately before the next appointment with provider Monitoring conducted over consecutive days is ideal; however, readings taken on nonconsecutive days may also provide valid data Analyzing readings For each monitoring period, the average of all readings should be obtained Some guidelines and scientific statements recommend excluding the first day of readings; if the first day of readings is excluded, the minimum and preferred periods of HBPM should be four and eight days, respectively For a video developed for patients by the VA and DoD with instructions on measuring blood pressure at home, please visit https://www.healthquality.va.gov/guidelines/CD/htn/ and click on the Home Blood Pressure Monitoring video. Appendix I: Participant List Angela A. Allerman, PharmD, BPCS Formulary Management Branch, Pharmacy Operations Division, Defense Health Agency San Antonio, TX Jennifer Ballard-Hernandez, DNP, NP, CCRN VA Central Office Washington, DC Dan Berlowitz, MD, MPH Edith Nourse Rogers Memorial Veterans Hospital Bedford, MA William C. Cushman, MD Co-Chair, VA Hypertension-Lipid Field Advisory Committee Chief, Preventive Medicine Section VA Medical Center Memphis, TN Elaine Furmaga, PharmD National Clinical Pharmacy Program Manager VA Pharmacy Benefits Management Services Hines, IL Peter Glassman, MBBs, MSc, FACP Chair, Medical Advisory Panel, Pharmacy Benefit Management Services, Department of Veterans Affairs Washington, DC Elvira O. Gosmanova, MD, FASN Albany Stratton VA Medical Center Albany, NY CDR Travis E. Harrell, MD, FACC, FACP Naval Medical Center San Diego, Department of Cardiology San Diego, CA Asha Jain, MA, RD, CDE Outpatient Nutrition Services Clinical Dietitian Walter Reed National Military Medical Center Bethesda, MD Lillian Pinault, MS, RD, CSG, CDE Baltimore VA Medical Center Baltimore, MD Pedro Roldan, MD, FAAFP VA Greater Los Angeles Healthcare System Los Angeles, CA Lt Col Joseph C Sky, MD, FACP, FACC Travis Air Force Base Travis, CA Addison Taylor, MD, PhD Michael E. DeBakey VA Medical Center Houston, TX LTC Tommy L. Thompson, DNP, FNP-C Assistant Clinical Professor Family Nurse Practitioner and Women s Health Nurse Practitioner Program Madigan Army Medical Center Tacoma, WA CDR Mark P. Tschanz, DO, MACM, FACP Naval Medical Center San Diego San Diego, CA Lt Col Jesse Wickham, DO, FACP Brooke Army Medical Center San Antonio, TX Appendix J: Literature Review Search Terms and Strategy A. EMBASE and Medline Embase.com Syntax Question Set # Concept Strategy Questions and Diagnosis and Management #1 Blood pressure blood pressure /exp OR blood pressure monitoring /exp OR diastolic blood pressure /exp OR systolic blood pressure /exp OR systole /de OR diastole /de #2 'blood pressure':ti,ab OR 'systolic pressure*':ti,ab OR 'diastolic pressure*':ti,ab OR 'arterial pressure*':ti,ab OR bp:ti,ab #3 (systol*:ti,ab OR diastol*:ti,ab OR arterial:ti,ab OR sbp:ti,ab OR dbp:ti,ab) AND (pressure*:ti,ab OR mmhg:ti,ab OR 'mm hg':ti,ab) #5 BP measurement, screening, or monitoring #4 AND (monitor* OR measure* OR record* OR screen* OR test* OR evaluat* OR track*):ti,ab OR monitoring /exp OR measurement /exp OR screening/exp) #6 ('blood pressure'/exp AND 'hypertension'/exp/dm_dm,dm_pc,dm_th) OR 'blood pressure monitoring'/exp OR blood pressure monitor /exp OR blood pressure measurement /exp) #8 Interventions/BP methods #4 AND ('ambulatory blood pressure'/exp OR 'ambulatory blood pressure measurement'/exp OR ambulatory monitoring /exp OR home monitoring /exp OR self care /exp OR self monitoring /exp OR general practice /de OR health center /de) #9 #4 AND (routine OR office* OR clinic OR clinics OR general practice OR kiosk OR primary care OR auscultatory OR center OR centers OR traditional OR standard OR attended OR unattended):ti #10 #4 AND ((office NEAR/3 blood pressure ) OR (office NEAR/3 BP )) #11 #4 AND (automated OR wake OR self-measure* OR self-record* OR self NEAR/2 monitor* OR self NEAR/2 manag* OR home OR out-of- office OR out of office OR day* OR night* OR evening OR bedtime OR bed time OR morning* OR 24-hour OR 24-hour OR home blood pressure monitoring OR HBPM OR home BP OR ambulatory OR ABPM OR (ambulatory NEAR/3 blood pressure ) OR (ambulatory NEAR/3 BP) OR tele-monitoring OR telemonitoring) #12 #4 AND (sphygmomanomet* OR oscillomet* OR manometer /exp OR sphymomanometer /exp) #15 Test characteristics predictive validity /de OR predictive value /de OR prognosis /de OR sensitivity and specificity /de OR diagnostic accuracy OR diagnostic test accuracy study /exp OR diagnostic value /exp OR hypertension /mj/dm_di #16 Predict*:ti,ab OR Prognos*:ti,ab OR Sensitivity:ti,ab OR Specificity:ti,ab OR accuracy:ti,ab OR accurate:ti,ab #17 (sensitiv* OR accura* OR specific* OR reliab* OR predict* OR prognostic):ti,ab Question Set # Concept Strategy Questions and Diagnosis and Management (cont.)


#19 Adherence and impact (Adhere* OR compliance OR comply OR goal OR goals OR threshold* OR achiev* OR benef* OR impact* OR improv* OR useful* OR utility):ti #20 adherence /exp OR patient compliance /exp OR treatment outcome /exp prehypertension 'hypertension'/exp OR 'hypertensive patient'/exp OR 'resistant hypertension'/exp OR 'masked hypertension'/exp OR 'white coat hypertension'/exp OR 'prehypertension'/exp #23 hypertension:ti,ab OR hypertensive:ti,ab OR 'borderline hypertensive':ti,ab OR prehyperten*:ti,ab OR 'white coat hypertension' OR wch OR 'masked hypertension' OR ((masked:ti,ab OR 'white coat':ti,ab OR borderline:ti,ab) AND hypertension:ti,ab) #24 (normal OR low OR high OR elevated OR borderline) NEAR/3 'blood pressure' #26 Combine BP and measure, screen, monitor, methods, accuracy #27 To diagnose and manage HTN #28 Combine BP and measure, screen, monitor, methods, adherence, and HTN Apply hedges below Questions and Non Pharmacological Interventions #1 hypertension 'hypertension'/exp OR 'hypertensive patient'/exp OR 'resistant hypertension'/exp OR 'masked hypertension'/exp OR 'white coat hypertension'/exp OR 'prehypertension'/exp #2 hypertension:ti,ab OR hypertensive:ti,ab OR 'borderline hypertensive':ti,ab OR (pre NEXT/1 hypertens*):ti,ab OR prehypertensi*:ti,ab OR 'white coat hypertension' OR wch OR 'masked hypertension' OR ((masked:ti,ab OR 'white coat':ti,ab OR borderline:ti,ab) AND hypertens*:ti,ab) #3 (high OR elevated OR borderline OR lower OR lowering) NEAR/3 'blood pressure' #5 'blood pressure'/exp OR 'diastolic blood pressure'/exp OR 'systolic blood pressure'/exp OR 'systole'/de OR 'diastole'/de #6 'blood pressure':ti,ab OR 'systolic pressure*':ti,ab OR 'diastolic pressure*':ti,ab OR 'arterial pressure*':ti,ab OR bp:ti,ab OR sbp:ti,ab OR dpb:ti,ab OR ((systol*:ti,ab OR diastol*:ti,ab OR arterial:ti,ab) AND (pressure*:ti,ab OR mmhg:ti,ab OR 'mm hg':ti,ab)) #8 Obesity 'obesity'/exp/mj OR 'obese patient'/exp/mj OR 'body mass'/exp OR 'body weight'/exp OR obese:ti OR obesity:ti OR overweight:ti Question Set # Concept Strategy Questions and Non Pharmacological Interventions (cont.)


#9 General treatment of overweight/obesity with the aim of preventing/ controlling hypertension 'obesity'/exp/dm_dm,dm_dt,dm_su,dm_th AND 'hypertension'/exp/dm_dm,dm_pc,dm_th #10 Obesity - pharma 'obesity'/exp/dm_dt OR 'tetrahydrolipstatin'/exp OR 'lorcaserin'/exp OR 'phentermine plus topiramate'/exp OR 'liraglutide'/exp OR ('obesity'/exp AND (antihypertensives OR 'anti hypertensives' OR (antihypertensive NEAR/1 drug*) OR ('anti hypertensive' NEAR/1 drug*))) OR 'antiobesity agent'/exp OR 'amfebutamone plus naltrexone'/de #11 phentemine OR topiramate OR qsymia OR lorcaserin OR belviq OR orlistat OR xenical OR alli OR (naltrexone NEXT/1 bupropion) OR contrave OR liraglutide OR saxenda OR victoza OR phentermine OR benzphetamine OR phendimetrazine OR diethylpropion OR (antiobesity NEXT/1 agent*) OR (antiobesity NEXT/1 drug*) OR (obesity NEXT/1 agent*) OR (obesity NEXT/1 drug*) #13 Obesity - surgery 'bariatric surgery'/exp OR 'roux-en-y gastric bypass'/exp OR 'obesity'/exp/dm_su #14 (obes*:ti,ab OR bariatric:ti,ab OR gastric*:ti,ab OR stomach:ti,ab OR 'weight loss':ti,ab) AND surg*:ti,ab #15 obes*:ti AND (sleeve*:ti,ab OR lapband*:ti,ab OR band*:ti,ab OR 'gastric bypass':ti OR gastrectomy:ti,ab OR 'roux n y':ti,ab OR 'roux- en-y':ti,ab OR 'roux en y':ti,ab OR rygb:ti,ab) #17 Obesity lifestyle modification 'body weight loss'/exp OR (('eating habit'/exp OR 'diet therapy'/exp OR 'healthy lifestyle'/exp OR 'obesity management'/exp OR 'sedentary lifestyle'/exp OR 'lifestyle modification'/exp) AND 'body weight'/exp) #18 (eat*:ti OR habit*:ti OR diet*:ti OR lifestyle*:ti OR sedentary:ti OR activity:ti OR active:ti OR activities:ti OR exercise:ti) AND (change*:ti OR modif*:ti OR improve*:ti OR manag*:ti) #19 (weight:ti OR 'body mass':ti) AND (lose:ti OR loss:ti OR lost:ti OR lowering:ti OR reduc*:ti OR manag*:ti) OR ((weight:ti OR 'body mass':ti) AND (diet*:ti OR nutrition*:ti OR food*:ti) AND (prescription:ti OR prescribed:ti)) OR (dash AND diet) OR (mediterranean AND diet) OR 'dietary approach* to stop hypertension' OR 'dash diet':ti,ab OR 'dash diet'/exp OR ((diet* OR nutrition*):ti,ab AND (sodium OR salt OR potassium):ti,ab)) #20 (weight:ti OR 'body mass':ti) AND (lose:ti OR loss:ti OR lost:ti OR lowering:ti OR reduc*:ti OR manag*:ti) #21 'obesity'/exp/mj AND 'lifestyle modification'/exp OR ((diet*:ti OR nutrition*:ti) AND ('bp':ti OR 'blood pressure':ti OR 'hypertension':ti OR 'cardiovascular disease':ti OR 'cvd':ti)) #23 Combine Obesity AND Obesity pharma #24 Combine Obesity AND surgery Question Set # Concept Strategy Questions and Non Pharmacological Interventions (cont.)


#25 Combine Obesity AND lifestyle mod #26 Combine final sets of Obesity 9 OR 23 OR 24 OR 25 #27 Physical activity 'exercise'/exp OR 'physical activity'/exp OR 'meditation'/exp OR 'transcendental meditation'/exp OR 'qigong'/exp OR 'qigong exercise'/exp OR 'tai chi'/exp OR 'yoga'/exp OR 'aerobic exercise'/exp OR 'physical activity, capacity and performance'/exp OR 'exercise intensity'/exp OR 'resistance training'/exp #28 exercise:ti,ab OR 'physical activity':ti,ab OR training:ti,ab OR isometric*:ti,ab OR 'weight training':ti,ab OR 'weight lift*':ti,ab OR 'resistance training':ti,ab OR walk* OR run* OR jog* OR stress*:ti,ab OR swim*:ti,ab OR aerobics OR (aerobic NEAR/3 exercis*) OR (aerobic NEAR/3 fitness) OR (aerobic NEAR/3 training) #29 qigong:ti,ab OR taichi:ti,ab OR 'tai chi':ti,ab OR yoga:ti,ab OR relax*:ti,ab OR meditat*:ti,ab #30 (exercise:ti OR ((physical NEAR/2 activity):ti)) AND (change*:ti OR improve*:ti OR modif*:ti OR increase*:ti) #31 sedentary:ti,ab OR 'sedentary lifestyle'/exp OR 'physical inactivity'/exp OR 'laziness'/exp #32 Combine final sets of physical activity #33 Combine HTN OR BP 4 OR 7 #34 Combine HTN OR BP with final obesity set #35 Combine HTN OR BP with final phys act set Apply hedges below Question Set # Concept Strategy Questions and Blood pressure thresholds and goals for pharmacologic interventions prehypertension.


WCH hypertension /exp OR hypertensive patient /exp OR resistant hypertension /exp OR masked hypertension /exp OR white coat hypertension /exp OR prehypertension /exp #2 Hypertension:ti,ab OR hypertensive:ti,ab OR borderline hypertensive :ti,ab OR prehyperten*:ti,ab OR white coat hypertension OR WCH OR masked hypertension OR ((masked OR white-coat OR white coat OR borderline):ti,ab AND hypertens*:ti,ab) #3 (high OR elevated OR borderline OR lower OR lowering) NEAR/3 blood pressure #5 Blood pressure 'blood pressure'/exp OR 'diastolic blood pressure'/exp OR 'systolic blood pressure'/exp OR 'systole'/de OR 'diastole'/de #6 'blood pressure':ti,ab OR 'systolic pressure*':ti,ab OR 'diastolic pressure*':ti,ab OR 'arterial pressure*':ti,ab OR bp:ti,ab OR sbp:ti,ab OR dpb:ti,ab OR ((systol*:ti,ab OR diastol*:ti,ab OR arterial:ti,ab) AND (pressure*:ti,ab OR mmhg:ti,ab OR 'mm hg':ti,ab)) mmhg':ti,ab OR '110 mmhg':ti,ab OR '120 mmhg':ti,ab OR '130 mmhg':ti,ab OR '140 mmhg':ti,ab OR '150 mmhg':ti,ab OR '160 mmhg':ti,ab OR '170 mmhg':ti,ab OR '180 mmhg':ti,ab #9 #8 AND ((best OR goal*:ti,ab OR standard*:ti,ab OR 'standard'/exp OR optimal:ti,ab OR ideal*:ti,ab OR target*:ti,ab) #10 'blood pressure goal*' OR 'blood-pressure goal*' OR 'blood pressure regulation'/exp #12 Antihypertensive drug therapy 'hypertension'/exp/dm_dt #13 'antihypertensive agent'/exp/mj OR 'antihypertensive therapy'/mj OR 'antihypertensive agent'/exp/dd_dt,dd_ad,dd_cm,dd_do #14 (antihypertens*:ti,ab OR 'anti hypertens*':ti,ab) AND (drug*:ti,ab OR pharma*:ti,ab OR medication*:ti,ab OR medicine*:ti,ab OR prescription*:ti,ab OR dose:ti,ab OR dosage:ti,ab) Apply hedges below Questions and Pharmacologic interventions prehypertension. WCH hypertension /exp OR hypertensive patient /exp OR resistant hypertension /exp OR masked hypertension /exp OR white coat hypertension /exp OR prehypertension /exp #2 Hypertension:ti,ab OR hypertensive:ti,ab OR borderline hypertensive :ti,ab OR prehyperten*:ti,ab OR white coat hypertension OR WCH OR masked hypertension OR ((masked OR white-coat OR white coat ):ti,ab AND hypertension:ti,ab) OR refractory hypertension :ti,ab OR resistant hypertension :ti,ab OR uncontrolled hypertension :ti,ab #3 (high OR elevated OR borderline OR low OR lowering) NEAR/3 blood pressure Question Set # Concept Strategy Questions and Pharmacologic interventions (cont.)


WCH hypertension /exp OR hypertensive patient /exp OR resistant hypertension /exp OR masked hypertension /exp OR white coat hypertension /exp OR prehypertension /exp #2 Hypertension:ti,ab OR hypertensive:ti,ab OR borderline hypertensive :ti,ab OR prehyperten*:ti,ab OR white coat hypertension OR WCH OR masked hypertension OR ((masked OR white-coat OR white coat ):ti,ab AND hypertension:ti,ab) OR refractory hypertension :ti,ab OR resistant hypertension :ti,ab OR uncontrolled hypertension :ti,ab #3 (high OR elevated OR borderline OR low OR lowering) NEAR/3 blood pressure Question Set # Concept Strategy Questions and Pharmacologic interventions (cont.) Antihypertensive Pharma therapy hypertension /exp/dm_dt OR ( hypertension /exp/mj AND antihypertensive agent /exp) #6 antihypertensive agent /exp/mj OR antihypertensive therapy /mj OR 'antihypertensive agent'/exp/dd_dt,dd_ad,dd_cm,dd_do #7 ((antihypertens* OR 'anti hypertens*') NEAR/5 (drug* OR pharma* OR medication* OR medicine* OR prescription* OR dose OR dosage)):ti,ab #8 Drugs (list is from workgroup members) Thiazide* OR thiazide-like diuretic* OR Chlorthalidone OR Bendroflumethiazide OR Chlorothiazide OR Hctz OR hydrochlorothiazide OR (hydrochlorothiazide NEAR/2 triamterene) OR Methyclothiazide OR Indapamide OR metolazone #9 Angiotensin-converting enzyme inhibitor* OR Benazepril OR captopril OR Enalapril OR Fosinopril OR Lisinopril OR moexipril OR Perindopril OR Quinapril OR Ramipril OR Trandolapril OR Angiotensin II Receptor Blocker* OR Azilsartan OR Candesartan OR Eprosartan OR Irbesartan OR Losartan OR Olmesartan OR Telmisartan OR Valsartan #10 Long-Acting Dihydropyridine Calcium Channel Blocker* OR dihydropyridine* OR CCBs OR Amlodipine OR Felodipine OR Nifedipine sr OR nifedipine xl OR nifedipine cc OR Nicardipine SR OR Nisoldipine ER #11 Aldosterone NEAR/2 Antagonist* OR mineralocorticoid Receptor Antagonist* OR Eplerenone OR Spironolactone OR Direct Renin Inhibitor OR Aliskiren OR Potassium-sparing diuretic* OR Amiloride #12 Alpha-blocker* OR Doxazosin OR Prazosin OR Terazosin OR Beta- blocker* OR Propranolol OR Acebutolol OR Atenolol OR Betaxolol OR Bisoprolol OR Metoprolol tartrate OR Metoprolol succinate OR Nadolol OR Nebivolol OR Penbutalol OR Pindolol OR Timolol #13 Long-Acting non-DHP CCB* OR non-dihydropyridine* OR Verapamil sr OR Diltiazem sr OR (alpha NEXT/2 beta NEXT/2 (antagonist* OR blocker*)) OR Carvedilol OR Labetalol OR Reserpine OR Minoxidil OR Hydralazine OR Clonidine tablet OR Clonidine patch OR Methyldopa OR Guanabenz OR Guanfacine #15 Combine HTN with drugs #4 AND #14 Apply hedges below Question Set # Concept Strategy Questions and Telehealth, mobile applications, or other new technologies; alternative methods of delivering care #1 Hypertension, prehypertension.


Antihypertensive Pharma therapy hypertension /exp/dm_dt OR ( hypertension /exp/mj AND antihypertensive agent /exp) #6 antihypertensive agent /exp/mj OR antihypertensive therapy /mj OR 'antihypertensive agent'/exp/dd_dt,dd_ad,dd_cm,dd_do #7 ((antihypertens* OR 'anti hypertens*') NEAR/5 (drug* OR pharma* OR medication* OR medicine* OR prescription* OR dose OR dosage)):ti,ab #8 Drugs (list is from workgroup members) Thiazide* OR thiazide-like diuretic* OR Chlorthalidone OR Bendroflumethiazide OR Chlorothiazide OR Hctz OR hydrochlorothiazide OR (hydrochlorothiazide NEAR/2 triamterene) OR Methyclothiazide OR Indapamide OR metolazone #9 Angiotensin-converting enzyme inhibitor* OR Benazepril OR captopril OR Enalapril OR Fosinopril OR Lisinopril OR moexipril OR Perindopril OR Quinapril OR Ramipril OR Trandolapril OR Angiotensin II Receptor Blocker* OR Azilsartan OR Candesartan OR Eprosartan OR Irbesartan OR Losartan OR Olmesartan OR Telmisartan OR Valsartan #10 Long-Acting Dihydropyridine Calcium Channel Blocker* OR dihydropyridine* OR CCBs OR Amlodipine OR Felodipine OR Nifedipine sr OR nifedipine xl OR nifedipine cc OR Nicardipine SR OR Nisoldipine ER #11 Aldosterone NEAR/2 Antagonist* OR mineralocorticoid Receptor Antagonist* OR Eplerenone OR Spironolactone OR Direct Renin Inhibitor OR Aliskiren OR Potassium-sparing diuretic* OR Amiloride #12 Alpha-blocker* OR Doxazosin OR Prazosin OR Terazosin OR Beta- blocker* OR Propranolol OR Acebutolol OR Atenolol OR Betaxolol OR Bisoprolol OR Metoprolol tartrate OR Metoprolol succinate OR Nadolol OR Nebivolol OR Penbutalol OR Pindolol OR Timolol #13 Long-Acting non-DHP CCB* OR non-dihydropyridine* OR Verapamil sr OR Diltiazem sr OR (alpha NEXT/2 beta NEXT/2 (antagonist* OR blocker*)) OR Carvedilol OR Labetalol OR Reserpine OR Minoxidil OR Hydralazine OR Clonidine tablet OR Clonidine patch OR Methyldopa OR Guanabenz OR Guanfacine #15 Combine HTN with drugs #4 AND #14 Apply hedges below Question Set # Concept Strategy Questions and Telehealth, mobile applications, or other new technologies; alternative methods of delivering care #1 Hypertension, prehypertension. WCH hypertension /exp OR hypertensive patient /exp OR resistant hypertension /exp OR masked hypertension /exp OR white coat hypertension /exp OR prehypertension /exp #2 Hypertension:ti,ab OR hypertensive:ti,ab OR borderline hypertensive :ti,ab OR prehyperten*:ti,ab OR white coat hypertension OR WCH OR masked hypertension OR ((masked OR white-coat OR white coat ):ti,ab AND hypertension:ti,ab) OR refractory hypertension :ti,ab OR resistant hypertension :ti,ab OR uncontrolled hypertension :ti,ab #3 (high OR elevated OR borderline OR lower OR lowering) NEAR/3 blood pressure #5 Blood Pressure 'blood pressure'/exp OR 'diastolic blood pressure'/exp OR 'systolic blood pressure'/exp OR 'systole'/de OR 'diastole'/de #6 'blood pressure':ti,ab OR 'systolic pressure*':ti,ab OR 'diastolic pressure*':ti,ab OR 'arterial pressure*':ti,ab OR bp:ti,ab OR sbp:ti,ab OR dpb:ti,ab OR ((systol*:ti,ab OR diastol*:ti,ab OR arterial:ti,ab) AND (pressure*:ti,ab OR mmhg:ti,ab OR 'mm hg':ti,ab)) #8 Telehealth 'telehealth'/exp OR 'teleconsultation'/exp OR 'telenursing'/exp OR 'telemedicine'/exp OR telemonitoring /exp OR videoconferencing /exp #9 telemedicine:ti,ab OR teleconsult*:ti,ab OR telehealth*:ti,ab OR telenurs*:ti,ab OR telemonitor*:ti,ab OR telecare:ti,ab OR telehomecare:ti,ab OR telemanagement:ti,ab OR telemedical*:ti,ab OR telemetr*:ti,ab OR 'tele medicin*':ti,ab OR 'tele health*':ti,ab OR tele-monitor* OR 'tele nurs*':ti,ab OR ehealth:ti,ab OR 'e health':ti,ab OR bluetooth:ti,ab OR (remote NEXT/2 consult*):ti,ab OR (telephone NEXT/2 consult*):ti,ab OR telephone:ti,ab #10 Technology mobile health application /exp OR 'mobile application'/exp OR mobile phone /exp OR smartphone /exp OR artificial intelligence /exp OR (email OR e-mail OR mhealth OR m-health OR mobile OR phone OR phones OR iphone* OR remote* OR virtual OR digital OR apps OR app OR text OR texting OR texts OR technology supported management OR technology based intervention* OR web based OR internet based OR computer based OR web):ti,ab #11 (device* OR monitors OR technologies OR smartwatch* OR smartphone OR watch* OR wearable OR wireless):ti,ab #12 social media /de OR ( crowd-sensing OR facebook OR social media ):ti,ab #13 Combine telehealth and technology #14 Combine HTN with tech #4 AND #13 #15 Combine BP with tech #7 AND #13 Question Set # Concept Strategy Questions and Telehealth, mobile applications, or other new technologies; alternative methods of delivering care (cont.)


#17 Other providers (nurse* OR nutritionist OR dietitian OR dietician OR pharmacist OR pharmacy OR clinic OR clinics OR specialist* OR nephrolog* OR cardiolog*):ti,ab) OR health care personnel /exp OR pharmacist /exp OR ( pharmacist run OR pharmacist led OR nurse led OR nurse run OR clinics OR clinic OR center OR centers):ti,ab #18 Collaborative team 'collaborative care team'/exp OR 'collaborative care':ti,ab OR 'community care' OR 'interdisciplinary communication' OR 'multi disciplinary':ti OR multidisciplinary:ti OR collaborative:ti OR teambased:ti,ab OR 'team based':ti,ab OR integrate:ti OR integrated:ti #19 Combine HTN AND other providers #20 Combine HTN AND tech AND other providers #21 Combine HTN AND collaborative #22 Combine HTN AND collaborative AND tech Apply hedges below Question Screening prehypertension. WCH hypertension /exp OR hypertensive patient /exp OR resistant hypertension /exp OR masked hypertension /exp OR white coat hypertension /exp OR prehypertension /exp #2 Hypertension:ti,ab OR hypertensive:ti,ab OR borderline hypertensive :ti,ab OR prehyperten*:ti,ab OR white coat hypertension OR WCH OR masked hypertension OR ((masked OR white-coat OR white coat ):ti,ab AND hypertension:ti,ab) OR refractory hypertension :ti,ab OR resistant hypertension :ti,ab OR uncontrolled hypertension :ti,ab #3 (high OR elevated OR borderline) NEAR/3 blood pressure #5 Disease/Conditions to screen for chronic kidney failure /exp/dm_di,dm_ep,dm_et OR 'end stage renal disease'/exp/dm_di,dm_ep,dm_et OR 'estimated glomerular filtration rate'/exp OR proteinuria /exp OR albuminuria /exp #6 chronic kidney disease :ti,ab OR CKD :ti,ab OR esrd :ti,ab OR egfr :ti,ab OR glomerular filtration rate :ti,ab #7 Albuminuria:ti,ab OR proteinuria:ti,ab OR (urine NEXT/1 protein):ti,ab OR (urine NEXT/1 albumin):ti,ab #8 coronary artery disease /exp/dm_di,dm_ep,dm_et OR coronary artery disease :ti,ab #9 'peripheral vascular disease'/exp/dm_di,dm_ep,dm_et OR peripheral vascular disease :ti,ab Question Set # Concept Strategy Question Screening (cont.)


WCH hypertension /exp OR hypertensive patient /exp OR resistant hypertension /exp OR masked hypertension /exp OR white coat hypertension /exp OR prehypertension /exp #2 Hypertension:ti,ab OR hypertensive:ti,ab OR borderline hypertensive :ti,ab OR prehyperten*:ti,ab OR white coat hypertension OR WCH OR masked hypertension OR ((masked OR white-coat OR white coat ):ti,ab AND hypertension:ti,ab) OR refractory hypertension :ti,ab OR resistant hypertension :ti,ab OR uncontrolled hypertension :ti,ab #3 (high OR elevated OR borderline) NEAR/3 blood pressure #5 Disease/Conditions to screen for chronic kidney failure /exp/dm_di,dm_ep,dm_et OR 'end stage renal disease'/exp/dm_di,dm_ep,dm_et OR 'estimated glomerular filtration rate'/exp OR proteinuria /exp OR albuminuria /exp #6 chronic kidney disease :ti,ab OR CKD :ti,ab OR esrd :ti,ab OR egfr :ti,ab OR glomerular filtration rate :ti,ab #7 Albuminuria:ti,ab OR proteinuria:ti,ab OR (urine NEXT/1 protein):ti,ab OR (urine NEXT/1 albumin):ti,ab #8 coronary artery disease /exp/dm_di,dm_ep,dm_et OR coronary artery disease :ti,ab #9 'peripheral vascular disease'/exp/dm_di,dm_ep,dm_et OR peripheral vascular disease :ti,ab Question Set # Concept Strategy Question Screening (cont.) #11 Screening Echo*:ti,ab OR ecg:ti,ab OR urine:ti,ab OR urine strip :ti,ab OR urinalysis:ti,ab OR ultrasound:ti,ab OR ankle-brachial index :ti,ab OR Doppler:ti,ab OR 'urinalysis'/exp OR 'urine test strip'/exp OR 'echography'/exp OR 'ultrasound'/exp OR 'Doppler flowmetry'/exp #12 'screening'/exp OR screen:ti,ab OR screening:ti,ab #13 'coronary calcium scoring'/exp OR 'coronary artery calcium score'/exp OR 'coronary calcium scor*' OR 'coronary calcium scan*' OR (cac AND artery) #15 Combine HTN and conditions and screening Apply hedges below General hedges applied to each section Date limit; Limit to English language publications; abstracts AND [1-12-2013]/sd NOT [11-3-2019]/sd AND [English]/lim AND [abstracts]/lim Remove undesired age ranges NOT (adolescen*:ti OR child*:ti OR infant*:ti OR neonat*:ti OR newborn*:ti OR paediatric*:ti OR pediatric*:ti OR youth:ti,ab) Remove undesired publication types (e.g.


#11 Screening Echo*:ti,ab OR ecg:ti,ab OR urine:ti,ab OR urine strip :ti,ab OR urinalysis:ti,ab OR ultrasound:ti,ab OR ankle-brachial index :ti,ab OR Doppler:ti,ab OR 'urinalysis'/exp OR 'urine test strip'/exp OR 'echography'/exp OR 'ultrasound'/exp OR 'Doppler flowmetry'/exp #12 'screening'/exp OR screen:ti,ab OR screening:ti,ab #13 'coronary calcium scoring'/exp OR 'coronary artery calcium score'/exp OR 'coronary calcium scor*' OR 'coronary calcium scan*' OR (cac AND artery) #15 Combine HTN and conditions and screening Apply hedges below General hedges applied to each section Date limit; Limit to English language publications; abstracts AND [1-12-2013]/sd NOT [11-3-2019]/sd AND [English]/lim AND [abstracts]/lim Remove undesired age ranges NOT (adolescen*:ti OR child*:ti OR infant*:ti OR neonat*:ti OR newborn*:ti OR paediatric*:ti OR pediatric*:ti OR youth:ti,ab) Remove undesired publication types (e.g., conferences, editorials) NOT ('conference paper'/exp OR 'case report'/de OR 'book'/de OR 'editorial'/de OR 'erratum'/de OR 'letter'/de OR 'note'/de OR 'short survey'/de OR book:it OR conference:it OR editorial:it OR erratum:it OR letter:it OR note:it OR 'short survey':it OR 'a case':ti,ab OR 'a patient':ti,ab OR 'year old':ti,ab OR book:pt OR 'conference proceeding':pt OR 'case report':ti OR comment:ti) Remove animal studies NOT (mouse OR mice OR rabbit* OR rat OR rats OR rodent* OR sheep OR swine OR canine* OR dog* OR porcine OR fish OR equine) Study type hedges applied as needed Limit to meta-analyses and systematic reviews AND ('meta analysis'/de OR 'systematic review'/de OR meta analysis /exp OR ('meta analysis' OR 'meta analytic' OR metaanaly* OR 'research synthesis' OR 'systematic review'/exp OR systematic review OR pooled OR pooling OR search*):ti,ab OR ('critical review' OR 'evidence based' OR systematic*):ti OR cochrane:jt OR [Cochrane review]/lim OR [systematic review]/lim OR [meta analysis]/lim OR ((systematic* NEAR/2 review*):ab,ti) OR metaanaly*:ab,ti OR meta analysis :ab,ti OR meta analyses :ab,ti) Limit to randomized controlled trials AND ('random sample'/de OR 'randomized controlled trial'/exp OR randomization/de OR random*:ti,ab OR randomized controlled trial /exp) Limit to comparative studies (used only when appropriate) AND ( case control study /exp OR 'cohort analysis'/de OR comparative study /exp OR controlled study /exp OR cross- sectional study /de OR diagnostic test accuracy study /de OR epidemiology/exp/mj OR follow up /de OR 'longitudinal study'/de OR observational study /de OR 'prospective study'/de OR retrospective study /de OR ( case control OR case series OR cohort OR compar* OR controlled study OR controlled trial OR cross sectional OR follow-up OR followup OR longitudinal OR matched controls OR placebo OR prospective OR retrospective):ti,ab OR (epidemiolog* OR versus OR vs):ti) B. PsycINFO with Ovid Syntax Question Set # Concept Strategy Questions and Treatments for obesity, lifestyle modifications, physical activity #1 Population (adults with hypertension) Exp hypertension/ OR Hypertension.mp.


OR hypertensive.mp. OR 'borderline hypertensive'.ti,ab. OR prehypertensi*.ti,ab. OR 'white coat hypertension' OR 'masked hypertension' #2 (high OR elevated OR borderline OR lower OR lowering) adj3 'blood pressure' #4 Obesity Exp Obesity/ OR obese.ti. OR obesity.ti. OR overweight.ti. #5 Obesity surgery Exp bariatric surgery/ OR exp weight control/ "roux en y".mp. OR "gastric bypass".mp. OR "obesity treatment".id. #6 (obes*.ti. OR bariatric.ti. OR gastric*.ti. OR stomach.ti. OR weight loss .ti. OR weight-loss.ti.) AND surg*.ti. #7 obes*.ti. and (sleeve or lapband or band* or "gastric bypass" or gastrectomy or "roux n y" or rygb).ti,ab. #8 Combine obesity surgery AND HTN #9 Obesity pharma Exp obesity AND exp drug therapy #10 (((tetrahydrolipstatin or lorcaserin or phentermine) adj2 topiramate) or liraglutide or phentemine or topiramate or phentemine or topiramate or qsymia or lorcaserin or belviq or orlistat or xenical or alli or (naltrexone adj1 bupropion) or contrave or liraglutide or saxenda or victoza or phentermine or benzphetamine or phendimetrazine or diethylpropion or (antiobesity adj1 agent*) or (antiobesity adj1 drug*) or (obesity adj1 agent*) or (obesity adj1 drug*)).mp. #11 ((antihypertensive* or "anti hypertensive*" or antihypertensive) adj1 drug*) or 'anti hypertensive') adj1 drug*).mp. or exp antiobesity agent/ #13 Combine obesity with pharma #14 Obesity lifestyle mod to control weight Exp weight control/ OR exp weight loss/ OR weight loss.mp. OR ((weight OR body mass) AND (lose OR loss OR lost OR lowering OR reduc* OR manag*)).ti. #15 Exp diets/ or diet therapy.mp. #16 (eat* OR diet* OR food OR sedentary OR lazy OR laziness OR activity OR active OR activities OR exercise).ti. AND (habit* OR choice* OR modif* OR change* OR improve* OR manag*).ti. #17 (Dash adj3 diet).mp. OR (Mediterranean adj3 diet).mp. OR ((diet* OR nutrition*).ti AND (sodium OR salt OR potassium).ti.) #18 exp Behavior Modification/ OR exp Lifestyle Changes/ OR lifestyle modification.mp.


#18 exp Behavior Modification/ OR exp Lifestyle Changes/ OR lifestyle modification.mp. #19 Combine weight control AND HTN #20 Combine diets AND HTN Question Set # Concept Strategy Questions and Treatments for obesity, lifestyle modifications, physical activity (cont.) #22 Exp meditation/ OR meditation.mp. OR exp mindfulness/ OR mindfulness.mp. OR qigong.mp. OR exp martial arts/ OR tai chi.mp. OR exp yoga/ OR yoga.mp. #23 Exp weightlifting/ OR resistance training.mp. #24 Exp running/ OR run*.ti. OR jog.ti. OR exp walking/ OR walk*.ti. OR swim*.ti. OR aerobics.ti. OR (aerobic adj2 exercise*).ti. OR (aerobic adj2 fitness).ti. OR (aerobic adj2 training).ti. #25 ((exericse or (physical adj2 activity)) and (change* or improve* or modif* or increase*)).ti. #26 Combine physical activity #27 Combine obesity AND phys activity #28 Combine obesity AND phys activity AND HTN #29 Exp sedentary behavior/ OR (sedentary OR inactive OR inactivity OR lazy OR laziness).ti,ab. #32 Apply limits See search hedges below Questions and Telehealth, mobile applications, or other new technologies; alternative methods of delivering care #1 Hypertension Exp hypertension/ #2 Hypertension.mp. OR hypertensive.mp. OR 'borderline hypertensive'.ti,ab. OR prehypertensi*.ti,ab. OR 'white coat hypertension' OR 'masked hypertension' #3 (high OR elevated OR borderline) adj3 'blood pressure' #5 Blood Pressure Exp blood pressure/ OR systolic pressure/ OR diastolic pressure/ #6 Blood pressure.ti,ab. OR systolic*.ti,ab OR diastolic.ti,ab. OR arterial pressure.ti,ab. OR bp.ti,ab. OR sbp.ti,ab. OR dbp.ti,ab. OR ((systole* OR diastol* OR arterial).ti. AND (pressure* OR mm hg OR mmgh).ti.) #8 Technology exp telemedicine/ or exp telenursing/ or exp remote consultation/ Question Set # Concept Strategy Questions and Telehealth, mobile applications, or other new technologies; alternative methods of delivering care (cont.)


#8 Technology exp telemedicine/ or exp telenursing/ or exp remote consultation/ Question Set # Concept Strategy Questions and Telehealth, mobile applications, or other new technologies; alternative methods of delivering care (cont.) #9 exp cellular phones/ or exp mobile devices/ or exp technology/ or exp electronic communication/ or exp internet/ or exp computer applications/ or exp online therapy/ or exp social media/ or exp websites/ or exp digital computers/ #10 ((cellular OR mobile) adj2 phone).ti. OR (telemedicine OR telehealth OR telenursing OR ehealth OR e health OR remote consult* OR telephone).ti. #11 ("personal digital assistant" OR smart phone OR cell* phone OR mobile phone OR smart watch OR androic* OR hand held OR iphone OR ipad OR webbased OR web based OR laptop OR "mobile health application" OR email OR e mail OR mhealth OR remote OR virtual OR digital OR apps OR app OR text OR texting OR texts OR "technology supported management" OR "technology based intervention" OR internet based or computer based).ti,ab. #12 (device* OR monitors OR technologies OR smartwatch* OR smartphone OR watch* OR wearable OR wireless OR "social media" OR facebook).ti,ab. #13 (telemedicine OR teleconsult* OR telehealth OR telenurs* OR telemonitor* OR telecare OR telehomecare OR telemanagement OR telemedical OR telemetr* OR ehealth OR bluetooth).ti,ab. OR (remote adj2 consult*).ti. OR (telephone adj2 consult*).ti. #15 Combine HTN AND Technology #16 Combine BP with Technology #17 Combine final technology sets #18 Allied health/delivery of care (nurse* OR nutritionist OR dietitian OR dietician OR pharmacist* OR pharmacy OR health care personnel).ti. OR (pharmacist adj1 run).ti,ab. OR (pharmacist adj1 led).ti,ab. OR (nurse adj1 led).ti,ab. OR (nurse adj1 run).ti,ab. OR (clinics OR clinic OR center OR centers).ti,ab.


OR (nurse adj1 run).ti,ab. OR (clinics OR clinic OR center OR centers).ti,ab. #19 exp health personnel/ OR exp pharmacists/ OR exp nurses/ #21 Combine delivery of care with HTN OR BP Apply limits and hedges See hedges below Question Set # Concept Strategy Search hedges applied to each strategy Limit to English language and publication year AND (english language AND yr="2013 - 2019") Population ("300 adulthood <age 18 yrs and older>" or 320 young adulthood <age 18 to 29 yrs> or 340 thirties <age 30 to 39 yrs> or 360 middle age <age 40 to 64 yrs> or "380 aged <age 65 yrs and older>" or "390 very old <age 85 yrs and older>") Exclude conference publications, books, letters, editorials, case studies, etc NOT ((("column/opinion" OR "comment/reply" OR dissertation OR editorial OR letter OR book).dt. OR book.pt.) OR (letter/ or editorial/ OR news/ OR comment/ OR case report OR case reports/ OR note/ OR conference paper/) OR (letter OR editorial OR news OR comment OR case reports OR conference abstract$).pt. Limit to meta-analyses and systematic reviews AND (meta analysis/ OR (systematic review OR meta analysis).mp. OR (meta-analysis OR systematic review).ti.) Limit to randomized controlled trials AND (Randomized controlled trials OR random allocation OR double-blind method OR single-blind method OR placebos OR cross-over studies).de. OR placebo$.mp. OR random$.ti. OR randomized controlled trial.pt. OR crossover$.mp. OR cross over.mp. OR ((singl* OR doubl* OR tripl* OR trebl*) ADJ3 (blind* OR mask* OR sham*)).mp. OR latin square.mp. OR ISRTCN OR ACTRN* OR (NCT* not NCT) OR (clinical trials/ AND random*.ti.)


OR ISRTCN OR ACTRN* OR (NCT* not NCT) OR (clinical trials/ AND random*.ti.) Limit to other study types, as needed AND (exp Cohort Analysis/ OR exp longitudinal studies/ OR exp prospective studies/ OR exp retrospective studies/ OR exp clinical trials/ OR (cohort* OR longitudinal OR prospective OR retrospective OR "case control" OR compar* OR "control group" OR "controlled study" OR "controlled trial" OR "cross over" OR crossover OR "double blind" OR "double blinded" OR "matched controls" OR placebo* OR random* OR sham OR validat*).ti,ab. OR ((versus OR vs).ti.) Limit to database study types AND ("0300 clinical trial" or "0430 followup study" or "0450 longitudinal study" or "0451 prospective study" or "0453 retrospective study" or "0830 systematic review" or 1200 meta analysis or 1300 metasynthesis or 2100 treatment outcome) Appendix K: Alternative Text Descriptions of Algorithms A. Module A: Screening and Diagnosis 1. Module A begins with Box 1, in the shape of a rounded rectangle: Adult in healthcare system 2. Box 1 connects to Box 2, in the shape of a hexagon, asks the question: Is the patient currently being treated for HTN? a. If the answer is Yes to Box 2, then Box 3, in the shape of an oval: Go to Module B, b. If the answer is No to Box 2, then Box 4, in the shape of a rectangle: Obtain office blood pressure (see Sidebar 1) 3. Box 4 connects to Box 5, in the shape of a hexagon, asks the question: When measured properly (see Appendix G), is SBP 120 mm Hg or DBP 80 mm Hg? a. If the answer is Yes to Box 5, then Box 6, in the shape of a hexagon, asks the question: Does patient have an acute injury or illness? i.


If the answer is Yes to Box 5, then Box 6, in the shape of a hexagon, asks the question: Does patient have an acute injury or illness? i. If the answer is Yes to Box 6, then Box 7, in the shape of a rectangle: Return after acute episode resolved (typically within 4 weeks) 1. Box 7 connects to Box 4, in the shape of a rectangle: Obtain office blood pressure (see Sidebar 1) ii. If the answer No to Box 6, then Box 8, in the shape of a rectangle: Assess the need for and implement lifestyle modification, then follow up for adherence (e.g., diet, exercise, weight loss, alcohol moderation) b. If the answer is No to Box 5, then Box 15, in the shape of a rectangle: Screen blood pressure periodically; address other CV risk factors (including healthy diet and physical activity); in patients with known or suspected target organ damage (see Sidebar 3), consider possibility of masked HTN (consider HBPM or ABPM) 4. Box 8 connects to Box 9, in the shape of a hexagon, asks the question: Is SBP 130 mm Hg or DBP 90 mm Hg a. If the answer is Yes to Box 9, then Box 10, in the shape of a hexagon, asks the question: Confirm diagnosis of HTN by measuring blood pressure after 1-4 weeks (see Sidebar 2); is diagnosis confirmed? i. If the answer is Yes to Box 10, then Box 11, in the shape of a rectangle: Obtain history and physical and assess for target organ damage and comorbid conditions (see Sidebar 3); consider baseline testing (e.g., basic metabolic panel, urinalysis, EKG, A1c, other tests), as appropriate ii.


, basic metabolic panel, urinalysis, EKG, A1c, other tests), as appropriate ii. If the answer is No to Box 10, then Box 15, in the shape of a rectangle: Screen blood pressure periodically; address other CV risk factors (including healthy diet and physical activity); in patients with known or suspected target organ damage (see Sidebar 3), consider possibility of masked HTN (consider HBPM or ABPM) b. If the answer is No to Box 9, then Box 15, in the shape of a rectangle: Screen blood pressure periodically; address other CV risk factors (including healthy diet and physical activity); in patients with known or suspected target organ damage (see Sidebar 3), consider possibility of masked HTN (consider HBPM or ABPM) 5. Box 11 connects to Box 12, in the shape of a hexagon, asks the question: Is secondary cause suspected? a. If the answer is Yes to Box 12, then Box 13, in the shape of a rectangle: Evaluate, as indicated; consider referral i. Box 13 connects to Box 14, in the shape of an oval: Initiate treatment (go to Module B) b. If the answer is No to Box 12, then Box 14, in the shape of an oval: Initiate treatment (go to Module B) B. Module B: Treatment 1. Module B begins with Box 16, in the shape of a rounded rectangle: Patient appropriate for HTN treatment 2. Box 16 connects to Box 17, in the shape of a rectangle: Determine blood pressure goal (see Sidebar 4) 3. Box 17 connects to Box 18, in the shape of a rectangle, asks the question: Implement SDM to assess patient values and preferences; assess the need for and implement lifestyle modification. Is the patient willing to engage in pharmacotherapy? a.


Box 17 connects to Box 18, in the shape of a rectangle, asks the question: Implement SDM to assess patient values and preferences; assess the need for and implement lifestyle modification. Is the patient willing to engage in pharmacotherapy? a. If the answer is Yes to Box 18, then Box 19, in the shape of an rectangle: Initiate treatment if drug na ve or optimize existing therapy (see Sidebar 5) b. If the answer is No to Box 18, then Box 20, in the shape of a rounded rectangle: Patient refuses pharmacotherapy; consider nurse-led and dietitian-led interventions to improve blood pressure control 4. Box 20 connects to Box 21, in the shape of a rounded rectangle: Follow up periodically; reassess preferences 5. Box 21 connects to Box 17, in the shape of a rectangle: Determine blood pressure goal (see Sidebar 4) 6. Box 19 connects to Box 22, in the shape of a rectangle: Consider offering and/or adjusting HBPM with co-interventions (tailored medication titration, education, and/or lifestyle counseling 7. Box 22 connects to Box 23, in the shape of a rectangle: Follow up regularly (e.g., monthly) until: blood pressure is at goal, treatment regimen is optimized (see Sidebar 6), comorbid conditions and/or other patient preferences direct otherwise 8. Box 23 connects to Box 24, in the shape of a hexagon, asks the question: Is the patient s blood pressure at or below goal? a. If the answer is Yes to Box 24, then Box 25, in the shape of a rectangle: Follow up annually or more frequently as dictated by comorbid conditions (to include lab monitoring, if indicated) b.


If the answer is Yes to Box 24, then Box 25, in the shape of a rectangle: Follow up annually or more frequently as dictated by comorbid conditions (to include lab monitoring, if indicated) b. If the answer is No to Box 24, then Box 22, in the shape of a rectangle: Consider offering and/or adjusting HBPM with co-interventions (tailored medication titration, education, and/or lifestyle counseling) Appendix L: Abbreviations Abbreviation Definition AASK African American Study of Kidney Disease and Hypertension AA aldosterone antagonist ABI ankle-brachial index ABPM ambulatory blood pressure monitoring ACC American College of Cardiology ACCOMPLISH Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension ACCORD Action to Control Cardiovascular Risk in Diabetes ACEI angiotensin-converting enzyme inhibitor ADVANCE Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation AE adverse effect AHA American Heart Association AHRQ Agency for Healthcare Research and Quality ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack ( AOBP automated office blood pressure ARB angiotensin II receptor blocker AUC area under curve AV atrioventricular bid twice daily BMI body mass index BPH benign prostatic hyperplasia BPROAD Blood Pressure Control Target in Diabetes CAC coronary artery calcification CAD coronary artery disease CCB calcium channel blocker CHF chronic heart failure CKD chronic kidney disease cm centimeter CMS Centers for Medicare and Medicaid Services COB central operating base COI conflict of interest COR contracting officer's representative CPG clinical practice guideline CS clinical study CV cardiovascular CVD cardiovascular disease DASH Dietary Approaches to Stop Hypertension DBP diastolic blood pressure DHP dihydropyridines Abbreviation Definition DoD Department of Defense DRI direct renin inhibitors EBPWG Evidence-Based Practice Work Group ECG electrocardiogram ECHO echocardiogram eGFR estimated glomerular filtration rate EKG electrocardiogram FDA U.S. Food and Drug Administration FOB forward operating base GI gastrointestinal GRADE Grading of Recommendations Assessment, Development and Evaluation HBPM home blood pressure monitoring HC high-unrefined carbohydrate, low-fat diet HCTZ hydrochlorothiazide HEC Health Executive Committee HFrEF reduced ejection fraction HIPAA Health Insurance Portability and Accountability Act HTN hypertension HYVET Hypertension in the Very Elderly Trial IPAD Intervention for High-normal or Borderline-elevated Blood Pressure in Adults with Type 2 Diabetes IR immediate release Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure K+ Potassium KQ key question LA DHP long-acting dihydropyridine LC low-carbohydrate, high-unsaturated/low-saturated fat diet LDL low-density lipoprotein LIFE Losartan Intervention For Endpoint reduction LV left ventricular LVH left ventricular hypertrophy MACE major adverse cardiovascular events MD mean difference MHS Military Health System MI myocardial infarction mL milliliter MRA mineralocorticoid receptor antagonist MRC Medical Research Council MRE Meals Ready to Eat MTF military treatment facilities Abbreviation Definition NHANES National Health and Nutrition Examination Survey NICE National Institute for Health and Care Excellence NPV negative predictive value OSA obstructive sleep apnea PCC patient-centered care PICOTS population, intervention, comparison, outcome, timing and setting PPV positive predictive value PREDIMED PREvenci n con DIeta MEDiterr nea PVD perpherial vascular disease RCT randomized control trial RHT resistant hypertension SBP systolic blood pressure SDM shared decision making SLE systemic lupus erythematosus SME subject matter expert SMS short message service SPRINT Systolic Blood Pressure Intervention Trial SR systematic review Tbsp tablespoon TOHP II Trials of Hypertension Prevention Phase II TONE Trial of Non-pharmacologic Interventions in the Elderly TOPCAT Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial U.S. United States US ultrasound USPSTF U.S. Preventive Services Task Force VA Veterans Affairs VHA Veterans Health Administration References 1.


U.S. Department of Veterans Affairs/Department of Defense Health Executive Committe (HEC). Evidence based practice work group charter. January 9, 2017. 2. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520. 3. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. Jama. May 21 2003;289(19): 2560-2572. PMID: 12748199. 4. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. Jun 2018; 71(6):e13-e115. PMID: 29133356. 5. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. Dec 14 2002;360(9349):1903-1913. PMID: 12493255. 6. Kaplan NM, Victor RG. Kaplan's clinical hypertension. 11 ed: Lippincott Williams & Wilkins (LWW); 2014. 7. Carretero OA, Oparil S. Essential hypertension. Part I: Definition and etiology. Circulation. Jan 25 2000;101(3): 329-335. PMID: 10645931. 8. Viera AJ, Neutze DM. Diagnosis of secondary hypertension: An age-based approach. Am Fam Physician. Dec 15 2010;82(12):1471-1478. PMID: 21166367. 9. National Center for Health Statistics. Health, United States. Health, United States, 2017: With special feature on mortality. Figure 010. Hyattsville (MD): National Center for Health Statistics (US); 2018. 10. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. Mar 1995;25(3):305-313. PMID: 7875754. 11.


Results from the third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. Mar 1995;25(3):305-313. PMID: 7875754. 11. Muntner P, Carey RM, Gidding S, et al. Potential US population impact of the 2017 ACC/AHA high blood pressure guideline. Circulation. Jan 9 2018;137(2):109-118. PMID: 29133599. 12. Smoley BA, Smith NL, Runkle GP. Hypertension in a population of active duty Service Members. J Am Board Fam Med. Nov-Dec 2008;21(6):504-511. PMID: 18988717. 13. Granado NS, Smith TC, Swanson GM, et al. Newly reported hypertension after military combat deployment in a large population-based study. Hypertension. Nov 2009;54(5):966-973. PMID: 19752293. 14. Shrestha A, Ho TE, Vie LL, et al. Comparison of cardiovascular health between US Army and civilians. Journal of the American Heart Association. 2019;8(12):e009056. 15. VA Health Services Research & Development. Spotlight: Hypertension and stroke. June 2011. http://www.hsrd.research.va.gov/news/feature/hyperrtension_stroke.cfm. Accessed September 11, 2019. 16. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: A report from the American Heart Association. Circulation. Mar 5 2019;139(10):e56-e528. PMID: 30700139. 17. U.S. Department of Veteran Affairs, Department of Defense. Guideline for guidelines. Veterans Health Administration, Office of Quality & Performance, Evidence Review Subgroup; Revised January 29, 2019. 18. Andrews JC, Schunemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol. Jul 2013;66(7): 726-735. PMID: 23570745. 19. Newberry SJ, Ahmadzai N, Motala A, et al. AHRQ methods for effective health care. Surveillance and identification of signals for updating systematic reviews: Implementation and early experience. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013. 20. Guirguis-Blake J, Calonge N, Miller T, Siu A, Teutsch S, Whitlock E. Current processes of the U.S. Preventive Services Task Force: Refining evidence-based recommendation development. Ann Intern Med. Jul 17 2007; 147(2):117-122. PMID: 17576998. 21. The guidelines manual.


Jul 17 2007; 147(2):117-122. PMID: 17576998. 21. The guidelines manual. London: National Institute for Health and Care Excellence;2012. http://www.nice.org.uk/article/pmg6/resources/non-guidance-the-guidelines-manual-pdf. 22. Martinez Garcia L, McFarlane E, Barnes S, Sanabria AJ, Alonso-Coello P, Alderson P. Updated recommendations: An assessment of NICE clinical guidelines. Implement Sci. 2014;9:72. PMID: 24919856. 23. Institute of Medicine (US) Committe on Standards for Developing Trustworthy Clinical Practice Guidelines, R Graham, M Mancher, D Miller Wolman, et al., editors. Clinical Practice Guidelines We Can Trust. Washington, DC: National Academies Press;2011. 24. Schunemann HJ, Fretheim A, Oxman AD. Improving the use of research evidence in guideline development: 10. Integrating values and consumer involvement. Health Res Policy Syst. 2006;4:22. PMID: 17147811. 25. Robinson JH, Callister LC, Berry JA, Dearing KA. Patient-centered care and adherence: definitions and applications to improve outcomes. J Am Acad Nurse Pract. Dec 2008;20(12):600-607. PMID: 19120591. 26. Stewart M, Brown JB, Donner A, et al. The impact of patient-centered care on outcomes. J Fam Pract. Sep 2000;49(9):796-804. PMID: 11032203. 27. Crossing the quality chasm: A new health system for the 21st century. Washington DC: National Academies Press;2001. 28. Society for Medical Decision Making Committee on Standardization of Clinical Algorithms. Proposal for clinical algorithm standards. Med Decis Making. Apr-Jun 1992;12(2):149-154. PMID: 1573982. 29. Wolff T, Miller T. Evidence for the reaffirmation of the U.S. Preventive Services Task Force recommendation on screening for high blood pressure. Ann Intern Med. Dec 4 2007;147(11):787-791. PMID: 18056663. 30. Siu AL, Force obotUSPST. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement screening for high blood pressure in adults. Annals of Internal Medicine. 2015; 163(10):778-786. 31. Ferrucci L, Furberg CD, Penninx BW, et al. Treatment of isolated systolic hypertension is most effective in older patients with high-risk profile. Circulation. Oct 16 2001;104(16):1923-1926. PMID: 11602495. 32.


Treatment of isolated systolic hypertension is most effective in older patients with high-risk profile. Circulation. Oct 16 2001;104(16):1923-1926. PMID: 11602495. 32. Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension. Feb 2000;35(2):539-543. PMID: 10679494. 33. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: Meta-analysis of outcome trials. Lancet. Mar 11 2000;355(9207):865-872. PMID: 10752701. 34. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: A cohort study. Lancet. Nov 17 2001; 358(9294):1682-1686. PMID: 11728544. 35. Piper MA, Evans CV, Burda BU, Margolis KL, O'Connor E, Whitlock EP. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: A systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. Feb 3 2015;162(3):192-204. PMID: 25531400. 36. Muntner P, Shimbo D, Carey RM, et al. Measurement of blood pressure in humans: A Scientific Statement From the American Heart Association. Hypertension. May 2019;73(5):e35-e66. PMID: 30827125. 37. Pappaccogli M, Di Monaco S, Perlo E, et al. Comparison of automated office blood pressure with office and out-off-office measurement techniques. Hypertension. Feb 2019;73(2):481-490. PMID: 30624994. 38. Roerecke M, Kaczorowski J, Myers MG. Comparing automated office blood pressure readings with other methods of blood pressure measurement for identifying patients with possible hypertension: A systematic review and meta-analysis. JAMA Intern Med. Feb 4 2019. PMID: 30715088. 39. Kollias A, Stambolliu E, Kyriakoulis KG, Gravvani A, Stergiou GS. Unattended versus attended automated office blood pressure: Systematic review and meta-analysis of studies using the same methodology for both methods. J Clin Hypertens (Greenwich). Feb 2019;21(2):148-155. PMID: 30585383. 40.


Unattended versus attended automated office blood pressure: Systematic review and meta-analysis of studies using the same methodology for both methods. J Clin Hypertens (Greenwich). Feb 2019;21(2):148-155. PMID: 30585383. 40. Picone DS, Schultz MG, Otahal P, et al. Accuracy of cuff-measured blood pressure: Systematic reviews and meta-analyses. J Am Coll Cardiol. Aug 1 2017;70(5):572-586. PMID: 28750701. 41. Sheppard JP, Albasri A, Franssen M, et al. Defining the relationship between arm and leg blood pressure readings: A systematic review and meta-analysis. J Hypertens. Dec 11 2018. PMID: 30585948. 42. Clark CE, McDonagh STJ, McManus RJ. Accuracy of automated blood pressure measurements in the presence of atrial fibrillation: Systematic review and meta-analysis. J Hum Hypertens. May 2019;33(5):352-364. PMID: 30631126. 43. Myers MG, Godwin M, Dawes M, et al. Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: Randomised parallel design controlled trial. Bmj. Feb 7 2011; 342:d286. PMID: 21300709. 44. Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. Jama. Mar 17 2004;291(11):1342-1349. PMID: 15026401. 45. Burr ML, Dolan E, O'Brien EW, O'Brien ET, McCormack P. The value of ambulatory blood pressure in older adults: The Dublin Outcome Study. Age Ageing. Mar 2008;37(2):201-206. PMID: 18349014. 46. Coll-de-Tuero G, Saez M, Roca-Saumell C, et al. Evolution of target organ damage by different values of self- blood pressure measurement in untreated hypertensive patients. American Journal of Hypertension. 2012; 25(12):1256-1263. 47. Ohkubo T, Imai Y, Tsuji I, et al. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: A population-based observation in Ohasama, Japan. J Hypertens. Jul 1998;16(7):971-975. PMID: 9794737. 48. Ohkubo T, Imai Y, Tsuji I, et al.


PMID: 9794737. 48. Ohkubo T, Imai Y, Tsuji I, et al. Prediction of mortality by ambulatory blood pressure monitoring versus screening blood pressure measurements: A pilot study in Ohasama. J Hypertens. Apr 1997;15(4):357-364. PMID: 9211170. 49. Mills KT, Obst KM, Shen W, et al. Comparative effectiveness of implementation strategies for blood pressure control in hypertensive patients: A systematic review and meta-analysis of implementation strategies for blood pressure control. Annals of Internal Medicine. 2018;168(2):110-120. 50. Tucker KL, Sheppard JP, Stevens R, et al. Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis. PLOS Medicine. 2017;14(9):e1002389. 51. Cuffee YL, Sciamanna C, Gerin W, et al. The effectiveness of home blood pressure on 24-hour blood pressure control: A randomized controlled trial. Am J Hypertens. Jan 15 2019;32(2):186-192. PMID: 30371759. 52. McManus RJ, Mant J, Franssen M, et al. Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): An unmasked randomised controlled trial. Lancet. Mar 10 2018;391(10124):949-959. PMID: 29499873. 53. Tzourio C, Hanon O, Godin O, Soumare A, Dufouil C. Impact of home blood pressure monitoring on blood pressure control in older individuals: A French randomized study. J Hypertens. Mar 2017;35(3):612-620. PMID: 27984412. 54. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis. Lancet. Mar 5 2016;387(10022):957-967. PMID: 26724178. 55. Saiz LC, Gorricho J, Garjon J, Celaya MC, Erviti J, Leache L. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. Cochrane Database Syst Rev. Jul 20 2018;7:Cd010315. PMID: 30027631. 56. Weiss J, Freeman M, Low A, et al. Benefits and harms of intensive blood pressure treatment in adults aged 60 years or older: A systematic review and meta-analysis. Ann Intern Med. Mar 21 2017;166(6):419-429.


Benefits and harms of intensive blood pressure treatment in adults aged 60 years or older: A systematic review and meta-analysis. Ann Intern Med. Mar 21 2017;166(6):419-429. PMID: 28114673. 57. Reboussin DM, Allen NB, Griswold ME, et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. Jun 2018; 71(6):e116-e135. PMID: 29133355. 58. Wright JT, Jr., Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. Nov 26 2015;373(22):2103-2116. PMID: 26551272. 59. Brunstrom M, Eliasson M, Nilsson PM, Carlberg B. Blood pressure treatment levels and choice of antihypertensive agent in people with diabetes mellitus: An overview of systematic reviews. J Hypertens. Mar 2017;35(3):453-462. PMID: 27870655. 60. Katsanos AH, Filippatou A, Manios E, et al. Blood pressure reduction and secondary stroke prevention: A systematic review and metaregression analysis of randomized clinical trials. Hypertension. Jan 2017;69(1): 171-179. PMID: 27802419. 61. Zonneveld TP, Richard E, Vergouwen MD, et al. Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev. Jul 19 2018;7:Cd007858. PMID: 30024023. 62. Sink KM, Evans GW, Shorr RI, et al. Syncope, hypotension, and falls in the treatment of hypertension: Results from the randomized clinical Systolic Blood Pressure Intervention Trial. J Am Geriatr Soc. Apr 2018;66(4): 679-686. PMID: 29601076. 63. Tinetti ME, McAvay GJ, Fried TR, et al. Health outcome priorities among competing cardiovascular, fall injury, and medication-related symptom outcomes. Journal of the American Geriatrics Society. 2008;56(8):1409-1416. PMID: 18662210. 64. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension.


Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP cooperative research group. Jama. Jun 26 1991;265(24):3255-3264. PMID: 2046107. 65. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The systolic hypertension in Europe (Syst-Eur) trial investigators. Lancet. Sep 13 1997;350(9080):757-764. PMID: 9297994. 66. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-713. 67. O'Connor PJ, Narayan KM, Anderson R, et al. Effect of intensive versus standard blood pressure control on depression and health-related quality of life in type 2 diabetes: The ACCORD trial. Diabetes Care. Jul 2012; 35(7):1479-1481. PMID: 22584134. 68. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. Jun 12 2008;358(24):2560-2572. PMID: 18539916. 69. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm hg. Jama. Dec 11 1967;202(11):1028-1034. PMID: 4862069. 70. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects morbidity of treatment on in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mm hg. JAMA. 1970;213(7):1143-1152. 71. Hypertension Detection and Follow-Up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. Jama. Dec 7 1979;242(23): 2562-2571. PMID: 490882. 72. Hypertension Detection and Follow-up Program Cooperative Group. The effect of treatment on mortality in mild hypertension. New England Journal of Medicine.


The effect of treatment on mortality in mild hypertension. New England Journal of Medicine. 1982;307(16):976-980. PMID: 7110301. 73. MRC Working Party. MRC trial of treatment of mild hypertension: Principal results. Medical Research Council Working Party. Br Med J (Clin Res Ed). Jul 13 1985;291(6488):97-104. PMID: 2861880. 74. Beddhu S, Chertow GM, Cheung AK, et al. Influence of baseline diastolic blood pressure on effects of intensive compared with standard blood pressure control. Circulation. Jan 9 2018;137(2):134-143. PMID: 29021322. 75. Greer N, Bolduc J, Geurkink E, et al. Pharmacist-led chronic disease management: A systematic review of effectiveness and harms compared with usual care. Ann Intern Med. Apr 26 2016. PMID: 27111098. 76. Santschi V, Chiolero A, Colosimo AL, et al. Improving blood pressure control through pharmacist interventions: A meta-analysis of randomized controlled trials. J Am Heart Assoc. Apr 10 2014;3(2):e000718. PMID: 24721801. 77. Bosworth HB, Olsen MK, McCant F, et al. Telemedicine cardiovascular risk reduction in veterans: The CITIES trial. Am Heart J. May 2018;199:122-129. PMID: 29754649. 78. Cheema E, Sutcliffe P, Weickert MO, Singer DRJ. A randomised controlled trial of the impact of structured written and verbal advice by community pharmacists on improving hypertension education and control in patients with high blood pressure. Eur J Clin Pharmacol. Nov 2018;74(11):1391-1395. PMID: 30022334. 79. Margolis KL, Asche SE, Dehmer SP, et al. Long-term outcomes of the effects of home blood pressure telemonitoring and pharmacist management on blood pressure among adults with uncontrolled hypertension: Follow-up of a cluster randomized clinical trial. JAMA Netw Open. Sep 7 2018;1(5):e181617. PMID: 30646139. 80. Victor RG, Blyler CA, Li N, et al. Sustainability of blood pressure reduction in black barbershops. Circulation. Jan 2 2019;139(1):10-19. PMID: 30592662. 81. Amer M, Rahman N, Nazir SR, et al.


PMID: 30592662. 81. Amer M, Rahman N, Nazir SR, et al. Impact of pharmacist's intervention on disease related knowledge, medication adherence, HRQoL and control of blood pressure among hypertensive patients. Pak J Pharm Sci. Nov 2018;31(6 (Supplementary):2607-2616. PMID: 30587468. 82. Zhu X, Wong FKY, Wu CLH. Development and evaluation of a nurse-led hypertension management model: A randomized controlled trial. Int J Nurs Stud. Jan 2018;77:171-178. PMID: 29100199. 83. Persell SD, Karmali KN, Lazar D, et al. Effect of electronic health record-based medication support and nurse- led medication therapy management on hypertension and medication self-management: A randomized clinical trial. JAMA Intern Med. Aug 1 2018;178(8):1069-1077. PMID: 29987324. 84. Ogedegbe G, Plange-Rhule J, Gyamfi J, et al. Health insurance coverage with or without a nurse-led task shifting strategy for hypertension control: A pragmatic cluster randomized trial in Ghana. PLoS Med. May 2018;15(5):e1002561. PMID: 29715303. 85. Sarfo F, Treiber F, Gebregziabher M, et al. PINGS (phone-based intervention under nurse guidance after stroke): Interim results of a pilot randomized controlled trial. Stroke. Jan 2018;49(1):236-239. PMID: 29222227. 86. Sarfo FS, Treiber F, Gebregziabher M, et al. Phone-based intervention for blood pressure control among Ghanaian stroke survivors: A pilot randomized controlled trial. Int J Stroke. Nov 22 2018:1747493018816423. PMID: 30465630. 87. Bolarinwa OA, Juni MH, Nor Afiah MZ, Salmiah MS, Akande TM. Mid-term impact of home-based follow-up care on health-related quality of life of hypertensive patients at a teaching hospital in Ilorin, Nigeria. Niger J Clin Pract. Jan 2019;22(1):69-78. PMID: 30666023. 88. Parappilly BP, Field TS, Mortenson WB, Sakakibara BM, Eng JJ. Effectiveness of interventions involving nurses in secondary stroke prevention: A systematic review and meta-analysis. Eur J Cardiovasc Nurs. Dec 2018; 17(8):728-736. PMID: 29856237. 89. Riegel GR, Ribeiro PAB, Rodrigues MP, Zuchinali P, Moreira LB.


Riegel GR, Ribeiro PAB, Rodrigues MP, Zuchinali P, Moreira LB. Efficacy of nutritional recommendations given by registered dietitians compared to other healthcare providers in reducing arterial blood pressure: Systematic review and meta-analysis. Clin Nutr. Apr 2018;37(2):522-531. PMID: 28065482. 90. World Health Organization. Mhelath: New horizons for health through mobile technologies. Global Observatory for eHealth. 7 June 2011 2011;3. 91. Liu S, Brooks D, Thomas SG, Eysenbach G, Nolan RP. Effectiveness of user- and expert-driven web-based hypertension programs: An rct. Am J Prev Med. Apr 2018;54(4):576-583. PMID: 29456025. 92. Nolan RP, Feldman R, Dawes M, et al. Randomized controlled trial of e-counseling for hypertension: REACH. Circ Cardiovasc Qual Outcomes. Jul 2018;11(7):e004420. PMID: 30006474. 93. Alessa T, Abdi S, Hawley MS, de Witte L. Mobile apps to support the self-management of hypertension: Systematic review of effectiveness, usability, and user satisfaction. JMIR Mhealth Uhealth. Jul 23 2018;6(7): e10723. PMID: 30037787. 94. Xiong S, Berkhouse H, Schooler M, et al. Effectiveness of mhealth interventions in improving medication adherence among people with hypertension: A systematic review. Curr Hypertens Rep. Aug 7 2018;20(10):86. PMID: 30088110. 95. Marquez Contreras E, Marquez Rivero S, Rodriguez Garcia E, et al. Specific hypertension smartphone app to improve medication adherence in hypertension: A cluster-randomized trial. Curr Med Res Opin. Nov 15 2018: 1-15. PMID: 30431384. 96. McLean G, Murray E, Band R, et al. Digital interventions to promote self-management in adults with hypertension: Protocol for Systematic review and meta-analysis. JMIR Res Protoc. Nov 20 2015;4(4):e133. PMID: 26589728. 97. Luo L, Ye M, Tan J, et al. Telehealth for the management of blood pressure in patients with chronic kidney disease: A systematic review. Journal of Telemedicine and Telecare. 2019;25(2):80-92. PMID: 29172929. 98. Vargas G, Cajita MI, Whitehouse E, Han HR. Use of short messaging service for hypertension management: A systematic review.


Use of short messaging service for hypertension management: A systematic review. J Cardiovasc Nurs. May/Jun 2017;32(3):260-270. PMID: 27111819. 99. Chen T-Y, Kao C-W, Cheng S-M, Chang Y-C. Effect of home medication titration on blood pressure control in patients with hypertension: A Meta-Analysis of randomized controlled trials. Medical care. 2019;57(3): 230-236. PMID: 30762831. 100. Beishuizen CR, Stephan BC, van Gool WA, et al. Web-based interventions targeting cardiovascular risk factors in middle-aged and older people: A systematic review and meta-analysis. J Med Internet Res. Mar 11 2016; 18(3):e55. PMID: 26968879. 101. Pan F, Wu H, Liu C, et al. Effects of home telemonitoring on the control of high blood pressure: A randomised control trial in the fangzhuang community health center, beijing. Aust J Prim Health. Nov 2018;24(5):398-403. PMID: 30131099. 102. Seetharamaiah S, Tantia O, Goyal G, et al. LSG vs OAGB 1 year follow-up data a randomized control trial. Obesity surgery. 2017;27(4):948-954. 103. Siebenhofer A, Jeitler K, Horvath K, et al. Long-term effects of weight-reducing drugs in people with hypertension. Cochrane Database Syst Rev. Mar 2 2016;3:Cd007654. PMID: 26934640. 104. Schiavon CA, Bersch-Ferreira AC, Santucci EV, et al. Effects of bariatric surgery in obese patients with hypertension: The GATEWAY Randomized Trial (gastric bypass to treat obese patients with steady hypertension). Circulation. Mar 13 2018;137(11):1132-1142. PMID: 29133606. 105. Yan Y, Sha Y, Yao G, et al. Roux-en-y gastric bypass versus medical treatment for type 2 diabetes mellitus in obese patients: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). Apr 2016;95(17):e3462. PMID: 27124041. 106. Tay J, Luscombe-Marsh ND, Thompson CH, et al. A very low-carbohydrate, low-saturated fat diet for type 2 diabetes management: A randomized trial. Diabetes Care. Nov 2014;37(11):2909-2918. PMID: 25071075. 107. Kucharska A, Gajewska D, Kiedrowski M, et al.


PMID: 25071075. 107. Kucharska A, Gajewska D, Kiedrowski M, et al. The impact of individualised nutritional therapy according to DASH diet on blood pressure, body mass, and selected biochemical parameters in overweight/obese patients with primary arterial hypertension: A prospective randomised study. Kardiol Pol. 2018;76(1):158-165. PMID: 28980293. 108. Semlitsch T, Jeitler K, Berghold A, et al. Long-term effects of weight-reducing diets in people with hypertension. Cochrane Database Syst Rev. Mar 2 2016;3:Cd008274. PMID: 26934541. 109. Zhang X, Devlin HM, Smith B, et al. Effect of lifestyle interventions on cardiovascular risk factors among adults without impaired glucose tolerance or diabetes: A systematic review and meta-analysis. PLoS One. 2017; 12(5):e0176436. PMID: 28493887. 110. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: A randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. Jama. Mar 18 1998;279(11):839-846. PMID: 9515998. 111. Herrod PJJ, Doleman B, Blackwell JEM, et al. Exercise and other nonpharmacological strategies to reduce blood pressure in older adults: A systematic review and meta-analysis. J Am Soc Hypertens. Apr 2018;12(4):248-267. PMID: 29496468. 112. Corso LM, Macdonald HV, Johnson BT, et al. Is concurrent training efficacious antihypertensive therapy? A meta-analysis. Med Sci Sports Exerc. Dec 2016;48(12):2398-2406. PMID: 27471784. 113. Maruf FA, Akinpelu AO, Salako BL, Akinyemi JO. Effects of aerobic dance training on blood pressure in individuals with uncontrolled hypertension on two antihypertensive drugs: A randomized clinical trial. J Am Soc Hypertens. Apr 2016;10(4):336-345. PMID: 26948962. 114. Bellissimo MP, Galaviz KI, Paskert MC, Lobelo F. Cardiometabolic risk reduction through recreational group sport interventions in adults: A systematic review and meta-analysis. Mayo Clin Proc. Oct 2018;93(10): 1375-1396. PMID: 30139702. 115. Reichert T, Costa RR, Barroso BM, da Rocha VdMB, Delevatti RS, Kruel LFM.


Reichert T, Costa RR, Barroso BM, da Rocha VdMB, Delevatti RS, Kruel LFM. Aquatic training in upright position as an alternative to improve blood pressure in adults and elderly: A systematic review and meta-analysis. Sports medicine (Auckland, N.Z.). 2018/07// 2018;48(7):1727-1737. PMID: 29651756. 116. Chan AWK, Chair SY, Lee DTF, et al. Tai chi exercise is more effective than brisk walking in reducing cardiovascular disease risk factors among adults with hypertension: A randomised controlled trial. Int J Nurs Stud. Dec 2018;88:44-52. PMID: 30195124. 117. Ma C, Zhou W, Tang Q, Huang S. The impact of group-based tai chi on health-status outcomes among community-dwelling older adults with hypertension. Heart Lung. Jul - Aug 2018;47(4):337-344. PMID: 29778251. 118. Yang H, Wu X, Wang M. The effect of three different meditation exercises on hypertension: A network meta- analysis. Evid Based Complement Alternat Med. 2017;2017:9784271. PMID: 28529532. 119. Wu Y, Johnson BT, Acabchuk RL, et al. Yoga as antihypertensive lifestyle therapy: A systematic review and meta-analysis. Mayo Clin Proc. Mar 2019;94(3):432-446. PMID: 30792067. 120. Kelley GA, Kelley KA, Tran ZV. Aerobic exercise and resting blood pressure: A meta-analytic review of randomized, controlled trials. Preventive cardiology. 2001;4(2):73-80. PMID: 11828203. 121. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: A meta-analysis of randomized, controlled trials. Ann Intern Med. Apr 2 2002;136(7):493-503. PMID: 11926784. 122. Sacks FM, Obarzanek E, Windhauser MM, et al. Rationale and design of the Dietary Approaches to Stop Hypertension trial (DASH). A multicenter controlled-feeding study of dietary patterns to lower blood pressure. Ann Epidemiol. Mar 1995;5(2):108-118. PMID: 7795829. 123. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. Apr 17 1997;336(16):1117-1124. PMID: 9099655. 124.


N Engl J Med. Apr 17 1997;336(16):1117-1124. PMID: 9099655. 124. Vollmer WM, Sacks FM, Ard J, et al. Effects of diet and sodium intake on blood pressure: Subgroup analysis of the DASH-sodium trial. Ann Intern Med. Dec 18 2001;135(12):1019-1028. PMID: 11747380. 125. Institute of Medicine. Dietary reference intakes for water, potassium, sodium, chloride, and sulfate. 2005. 126. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. Jan 4 2001;344(1):3-10. PMID: 11136953. 127. Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: Observational follow-up of the Trials of Hypertension Prevention (TOHP). Bmj. Apr 28 2007; 334(7599):885-888. PMID: 17449506. 128. Kumanyika SK, Cook NR, Cutler JA, et al. Sodium reduction for hypertension prevention in overweight adults: Further results from the Trials of Hypertension Prevention Phase II. J Hum Hypertens. Jan 2005;19(1):33-45. PMID: 15372064. 129. Shea MK, Nicklas BJ, Houston DK, et al. The effect of intentional weight loss on all-cause mortality in older adults: Results of a randomized controlled weight-loss trial. Am J Clin Nutr. Sep 2011;94(3):839-846. PMID: 21775558. 130. U.S. Department of Health and Human Services and U.S. Department of Agriculture. 2015 2020 dietary guidelines for americans. 2015. 131. Quader ZS ZL, Gillespie C, et al. Sodium intake among persons aged 2 years United States, 2013 2014. MMWR Morb Mortal Wkly Rep. 2017 66(12):324-238. 132. Toledo E, Hu FB, Estruch R, et al. Effect of the Mediterranean diet on blood pressure in the PREDIMED trial: Results from a randomized controlled trial. BMC Med. Sep 19 2013;11:207. PMID: 24050803. 133. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet.


Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. Apr 4 2013;368(14):1279-1290. PMID: 23432189. 134. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. Jun 21 2018;378(25):e34. PMID: 29897866. 135. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta- analyses. J Hypertens. Jul 2015;33(7):1321-1341. PMID: 26039526. 136. Wright JT, Jr., Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. Jama. Apr 6 2005;293(13):1595-1608. PMID: 15811979. 137. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack trial (ALLHAT). JAMA. Dec 18 2002;288(23):2981-2997. PMID: 12479763. 138. Leenen FH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid- lowering treatment to prevent heart attack trial. Hypertension. Sep 2006;48(3):374-384. PMID: 16864749. 139. Julius S, Alderman MH, Beevers G, et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: The LIFE study. J Am Coll Cardiol. Mar 17 2004;43(6):1047-1055. PMID: 15028365. 140. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. Jama. Jun 6 2001;285(21):2719-2728. PMID: 11386927. 141. Rahman M, Ford CE, Cutler JA, et al. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack trial (ALLHAT) participants by baseline estimated GFR.


Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack trial (ALLHAT) participants by baseline estimated GFR. Clin J Am Soc Nephrol. Jun 2012;7(6):989-1002. PMID: 22490878. 142. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 - effects of different classes of antihypertensive drugs in older and younger patients: Overview and meta-analysis. J Hypertens. Aug 2018;36(8):1637-1647. PMID: 29847487. 143. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-1898. PMID: 18378519. 144. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. Dec 4 2008;359(23):2417-2428. PMID: 19052124. 145. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. Nov 14 2013;369(20):1892-1903. PMID: 24206457. 146. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. Dec 6 2012;367(23):2204-2213. PMID: 23121378. 147. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. Apr 10 2008;358(15):1547-1559. PMID: 18378520. 148. Cushman WC, Ford CE, Einhorn PT, et al. Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack trial (ALLHAT). J Clin Hypertens (Greenwich). Oct 2008; 10(10):751-760. PMID: 19090876. 149. Salam A, Kanukula R, Atkins E, et al. Efficacy and safety of dual combination therapy of blood pressure- lowering drugs as initial treatment for hypertension: A systematic review and meta-analysis of randomized controlled trials. J Hypertens. Sep 2019;37(9):1768-1774. PMID: 30986788. 150. Liu L, Xu B, Ju Y.